Papers
Research literature with structured metadata.
Trials
Registered studies by status, phase, and compound.
Topics
Indications and themes psychedelics are researched for.
Compounds
Evidence across molecules with rich data.
Countries
Regulation, access, and research activity by region.
Stakeholders
Organizations shaping the space across research, policy, and funding.
People
Investigators, clinicians, and authors with mapped output.
Courses
Training programs and certifications across modalities.
Events
Conferences, workshops, and convenings by date and focus.
Research recaps
Monthly evidence summaries with key takeaways.
Map of research
Landscape view of trials, compounds, and outcomes.
Newsletter
Weekly or daily updates on trials, publications, analysis, and more.
Research Groups
Worldwide map of psychedelic research centres by region.
Research Network
Interactive co-authorship map of psychedelic researchers.
Top papers
Find needles in the haystack of psychedelic research per topic.
This open-label study (n=94) finds that baseline plasma BDNF concentrations (a protein related to nerve growth) correlate with ketamine (6 infusions, 35mg/70kg) antidepressant effects (MADRS).
Harmine markedly increases proliferation of human neural progenitor cells (hNPCs) derived from pluripotent stem cells, enlarging the proliferating pool by 71.5% after four days in vitro. The proliferation was mimicked by the DYRK1A inhibitor INDY but not by the MAO inhibitor pargyline, implicating DYRK1A inhibition as a likely mechanism and potentially explaining harmine’s antidepressant effects.